Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.073
Buy
RSI(14)
72.733
Buy
STOCH(KDJ)(9,3,3)
76.855
Buy
ATR(14)
0.877
High Vlolatility
CCI(14)
259.058
Overbought
Williams %R
9.890
Overbought
TRIX(12,20)
0.849
Sell
StochRSI(14)
100.000
Buy
Enanta Pharmaceuticals Inc
ENTA15.979USD
-0.231-1.43%
Market hours （ET）Quotes delayed by 15 min
341.74MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Enanta Pharmaceuticals Inc
Currency: USD Updated: 2025-12-22Key Insights
Enanta Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 63/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Enanta Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
19.000
Target Price
+33.99%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Enanta Pharmaceuticals Inc Highlights
StrengthsRisks
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Growing
The company is in a growing phase, with the latest annual income totaling USD 65.32M.
Undervalued
The company’s latest PE is -4.22, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 19.84M shares, increasing 6.96% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.90K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of Enanta Pharmaceuticals Inc is 7.30, ranking 118/158 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 15.12M, representing a year-over-year increase of 3.55%, while its net profit experienced a year-over-year increase of 35.12%.
Score
Financials
4.92
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.99
Operational Efficiency
10.00
Growth Potential
7.37
Shareholder Returns
7.23
Enanta Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of Enanta Pharmaceuticals Inc is 7.10, ranking 99/158 in the Pharmaceuticals industry. Its current P/E ratio is -4.22, which is -77.78% below the recent high of -0.94 and -121.89% above the recent low of -9.37.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 63/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of Enanta Pharmaceuticals Inc is 8.25, ranking 45/158 in the Pharmaceuticals industry. The average price target for Enanta Pharmaceuticals Inc is 20.00, with a high of 28.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
19.000
Target Price
+33.99%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Enanta Pharmaceuticals Inc
ENTA
8
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of Enanta Pharmaceuticals Inc is 8.84, ranking 56/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 17.56 and the support level at 13.78, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
15.046
Buy
MA10
14.798
Buy
MA20
14.428
Buy
MA50
12.561
Buy
MA100
10.627
Buy
MA200
8.506
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of Enanta Pharmaceuticals Inc is 7.00, ranking 44/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 81.86%, representing a quarter-over-quarter decrease of 29.86%. The largest institutional shareholder is The Vanguard, holding a total of 1.94M shares, representing 6.72% of shares outstanding, with 28.47% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Farallon Capital Management, L.L.C.
Krensavage Asset Management, LLC
Janus Henderson Investors
BlackRock Institutional Trust Company, N.A.
Millennium Management LLC
Acadian Asset Management LLC
Luly (Jay R)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of Enanta Pharmaceuticals Inc is 1.91, ranking 138/158 in the Pharmaceuticals industry. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.96
VaR
+5.85%
240-Day Maximum Drawdown
+49.82%
240-Day Volatility
+85.42%
Return
Best Daily Return
60 days
+91.90%
120 days
+91.90%
5 years
+91.90%
Worst Daily Return
60 days
-21.04%
120 days
-21.04%
5 years
-25.66%
Sharpe Ratio
60 days
+2.22
120 days
+1.57
5 years
-0.00
Risk Assessment
Maximum Drawdown
240 days
+49.82%
3 years
+91.97%
5 years
+95.62%
Return-to-Drawdown Ratio
240 days
+4.03
3 years
-0.25
5 years
-0.14
Skewness
240 days
+7.60
3 years
+6.99
5 years
+6.39
Volatility
Realised Volatility
240 days
+85.42%
5 years
+68.30%
Standardised True Range
240 days
+3.65%
5 years
+10.10%
Downside Risk-Adjusted Return
120 days
+424.42%
240 days
+424.42%
Maximum Daily Upside Volatility
60 days
+190.30%
Maximum Daily Downside Volatility
60 days
+64.11%
Liquidity
Average Turnover Rate
60 days
+0.80%
120 days
+0.86%
5 years
--
Turnover Deviation
20 days
-43.65%
60 days
-34.08%
120 days
-28.68%
Peer Comparison
Pharmaceuticals
Enanta Pharmaceuticals Inc
ENTA
7.20 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.71 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Enanta Pharmaceuticals Inc?
The TradingKey Stock Score provides a comprehensive assessment of Enanta Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Enanta Pharmaceuticals Inc’s performance and outlook.
How do we generate the financial health score of Enanta Pharmaceuticals Inc?
To generate the financial health score of Enanta Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Enanta Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Enanta Pharmaceuticals Inc.
How do we generate the company valuation score of Enanta Pharmaceuticals Inc?
To generate the company valuation score of Enanta Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Enanta Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Enanta Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Enanta Pharmaceuticals Inc.
How do we generate the earnings forecast score of Enanta Pharmaceuticals Inc?
To calculate the earnings forecast score of Enanta Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Enanta Pharmaceuticals Inc’s future.
How do we generate the price momentum score of Enanta Pharmaceuticals Inc?
When generating the price momentum score for Enanta Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Enanta Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Enanta Pharmaceuticals Inc.
How do we generate the institutional confidence score of Enanta Pharmaceuticals Inc?
To generate the institutional confidence score of Enanta Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Enanta Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Enanta Pharmaceuticals Inc.
How do we generate the risk management score of Enanta Pharmaceuticals Inc?
To assess the risk management score of Enanta Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Enanta Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Enanta Pharmaceuticals Inc.
